October 13, 2022
LexaGene announces that it has received an indication that a major biopharma company intends to purchase its technology.
September 1, 2022
LexaGene announces that it has entered into a purchase agreement with a veterinary hospital in southern California.
LexaGene Verifies CDC Monkeypox Assay Works on MiQLab System and Readies Company Should an EUA be Declared
August 29, 2022
LexaGene announces the MiQLab® System can perform the Centers for Disease Control and Prevention (CDC) Monkeypox real-time PCR test.
LexaGene’s MiQLab System Generates Leptospira Results in as Soon as 30 minutes using Isothermal Chemistry
August 24, 2022
LexaGene has successfully configured the MiQLab System to use isothermal chemistry for individual pathogen detection in as soon as 30 minutes.
University of Pennsylvania’s School of Veterinary Medicine to Evaluate New Gastrointestinal Panel Using LexaGene’s MiQLab System
August 17, 2022
LexaGene announces the start of an evaluation of a gastrointestinal (GI) pathogen panel.
August 10, 2022
LexaGene has shortened the time the MiQLab® System needs to report a result by ~35%.
LexaGene Announces Filing of Financial Statements, Revocation of MCTO & the Granting of Incentive Equity Awards to Employees
July 29, 2022
LexaGene has filed financial statements and granted incentive equity awards to employees.
LexaGene Completes Multi-Center Validation Study Using MiQLab® System for Diagnosing Urinary Tract Infections
July 27, 2022
LexaGene provides a summary of preliminary data collected during a clinical validation study.
July 12, 2022
LexaGene continues to make progress on Annual Financial Filings.
LexaGene Announces Webinar by UC Davis Professor on Use of MiQLab® System for Diagnosis of Urinary Tract Infections
July 5, 2022
UC Davis Professor Jane Sykes presents a webinar on a multi-center study using the MiQLab to diagnose urinary tract infections
For Marketing inquiries, please email: